A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in Badalona provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer (CRC). These are two tumor types in which the same oncogenic alteration—the BRAFV600E mutation—results in markedly different therapeutic outcomes when treated with BRAF inhibitors.
This article was originally published on MedicalXpress.com
